Compare MRCC & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCC | INBX |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.8M | 1.1B |
| IPO Year | 2011 | 2024 |
| Metric | MRCC | INBX |
|---|---|---|
| Price | $4.62 | $68.74 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 155.4K | 133.7K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | ★ 14.85% | N/A |
| EPS Growth | N/A | ★ 649.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $200,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.11 | $10.81 |
| 52 Week High | $7.99 | $94.57 |
| Indicator | MRCC | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 33.74 | 39.32 |
| Support Level | N/A | $28.54 |
| Resistance Level | $6.91 | $85.97 |
| Average True Range (ATR) | 0.32 | 4.31 |
| MACD | -0.08 | -0.73 |
| Stochastic Oscillator | 26.23 | 10.57 |
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.